Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Gene |
RCV001768245 | SCV002008735 | uncertain significance | not provided | 2019-09-25 | criteria provided, single submitter | clinical testing | In silico analysis, which includes protein predictors and evolutionary conservation, supports that this variant does not alter protein structure/function; Has not been previously published as pathogenic or benign to our knowledge |
Fulgent Genetics, |
RCV002482284 | SCV002789869 | uncertain significance | Diabetes mellitus type 1; Type 1 diabetes mellitus 20; Maturity-onset diabetes of the young type 3; Type 2 diabetes mellitus; Hepatic adenomas, familial; Nonpapillary renal cell carcinoma | 2022-05-07 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001768245 | SCV003241985 | likely benign | not provided | 2025-01-26 | criteria provided, single submitter | clinical testing | |
Prevention |
RCV004753387 | SCV005344494 | uncertain significance | HNF1A-related disorder | 2024-06-28 | no assertion criteria provided | clinical testing | The HNF1A c.1756G>A variant is predicted to result in the amino acid substitution p.Ala586Thr. To our knowledge, this variant has not been reported in the literature. This variant is reported in 0.063% of alleles in individuals of African descent in gnomAD. Although we suspect that this variant may be benign, at this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. |